-
公开(公告)号：EP3230472A1
公开(公告)日：2017-10-18
申请号：EP15866475.5
申请日：2015-12-08
申请人： Myriad Genetics, Inc. , Tesaro Inc.
发明人： WILCOXEN, Keith , LANCHBURY, Jerry , GUTIN, Alexander , TIMMS, Kirsten , ABKEVICH, Victor , WANG, Yan
IPC分类号： C12Q1/68 , G06F19/22 , A61K31/416
CPC分类号： C12Q1/6886 , A61K31/454 , C12Q2600/106 , C12Q2600/158
摘要： This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature to predict response to niraparib. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature to predict response to niraparib are provided.
摘要翻译： 该文件提供了评估样本（例如癌细胞）是否存在同源重组缺陷（HRD）或HRD签名以预测对尼拉帕利布的反应的方法和材料。 例如，提供了用于确定细胞（例如癌细胞）是否含有HRD标签以预测对niraparib的反应的方法和材料。
-
公开(公告)号：EP3862440A1
公开(公告)日：2021-08-11
申请号：EP21162699.9
申请日：2011-06-17
IPC分类号： C12Q1/6827 , A61P35/00 , C12Q1/6886 , G16B20/00
摘要： This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
公开(公告)号：EP2794907B1
公开(公告)日：2019-11-13
申请号：EP12860530.0
申请日：2012-12-21
-
公开(公告)号：EP3134548A2
公开(公告)日：2017-03-01
申请号：EP15782948.2
申请日：2015-04-22
发明人： LANCHBURY, Jerry , GUTIN, Alexander , FLAKE, Darl
IPC分类号： C12Q1/68 , G01N33/50 , G01N33/574 , G06F19/10
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N2800/52 , G01N2800/54 , G06F19/18 , G06F19/20 , G06F19/24
摘要： The disclosure provides for molecular classification of disease and, particularly, molecular markers for breast cancer prognosis and methods and systems of use thereof.
摘要翻译： 本公开提供疾病的分子分类，特别是乳腺癌预后的分子标记及其使用方法和系统。
-
公开(公告)号：EP4139490A2
公开(公告)日：2023-03-01
申请号：EP21792913.2
申请日：2021-04-16
IPC分类号： C12Q1/6886 , C12Q1/6809 , G01N37/00 , C12M1/34
-
公开(公告)号：EP3012329B1
公开(公告)日：2017-10-25
申请号：EP15189527.3
申请日：2011-06-17
CPC分类号： C12Q1/6886 , C12Q1/6827 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G06F19/18 , C12Q2537/16
-
公开(公告)号：EP2582847A2
公开(公告)日：2013-04-24
申请号：EP11796544.2
申请日：2011-06-17
申请人： Myriad Genetics, Inc. , Abkevich, Victor , Gutin, Alexander , Timms, Kirsten , Lanchbury, Jerry
CPC分类号： C12Q1/6886 , C12Q1/6827 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G06F19/18 , C12Q2537/16
摘要： This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
8.发明公开
公开(公告)号：EP4444914A1
公开(公告)日：2024-10-16
申请号：EP22905049.7
申请日：2022-12-06
IPC分类号： C12Q1/6886 , G01N33/574
-
-
公开(公告)号：EP2582847B1
公开(公告)日：2016-10-26
申请号：EP11796544.2
申请日：2011-06-17
CPC分类号： C12Q1/6886 , C12Q1/6827 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G06F19/18 , C12Q2537/16
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.021 秒)
